The Impact of FSH Isoforms on Follicular Development - Understanding the combined role of FSH and Inhibin-B in Follicular Development Across the Follicular Phase
1. The Interplay between Inhibin B and Androgens in Follicular Development
Professor Andersen highlighted a significant and dose-dependent relationship between inhibin B levels and the concentrations of testosterone and androstenedione within small antral follicles (measuring 4 to 12 millimetres in diameter). This correlation indicates that higher inhibin B concentrations are directly linked to elevated androgen levels within the follicular microenvironment. Critically, the granulosa cells corresponding to these androgen-rich follicles demonstrated significantly increased expression of FSH receptor (FSHR), LH receptor (LHR), and aromatase (CYP19A1). This intricate relationship underscores a direct mechanistic link: inhibin B influences androgen production, which in turn enhances the follicle’s capacity to respond to gonadotropins (FSH and LH) and to convert androgens into oestrogens.
2. Androgen Receptor and FSH Receptor Expression: Enhancing Follicular Sensitivity
A pivotal insight presented was the direct correlation between the expression of the androgen receptor (AR) and the FSH receptor (FSHR) in granulosa cells. This means that a higher presence of androgen receptors, signifying a greater local androgen concentration within the follicle, directly corresponds to an increased expression of FSH receptors. This mechanism is fundamental: elevated androgen levels render the follicle more sensitive and responsive to FSH stimulation, thereby promoting enhanced follicular growth and development. This finding provides a physiological explanation for clinical observations where specific FSH isoforms, particularly more acidic variants, appear to stimulate greater follicular recruitment, likely by upregulating androgen production and subsequently increasing FSH sensitivity.
3. Unphysiological Testosterone Administration vs. Local Androgen Production
Professor Andersen reviewed historical data, including studies on monkeys from Caroline Bundis’ group (dating back over 25 years), which demonstrated that exogenous testosterone administration could enhance FSH receptor expression and increase follicular recruitment. However, he underscored a crucial distinction: the testosterone doses used in these animal models (e.g., 4 mg/kg for 8 days or 0.4 mg/kg for 10 days) are supraphysiological and clinically unfeasible in women. Doses exceeding approximately 0.1 mg/day in women can induce masculinising features, rendering such systemic administration impractical and unsafe for fertility treatments.
This highlights a fundamental principle: while androgens are potent regulators of follicular development, their mode of delivery is paramount (local production versus circulation). Recent research from Professor Andersen’s group has shown that intra-follicular androgen concentrations are orders of magnitude higher than systemic levels, reaching 200-400 nanomolar within the follicles compared to approximately 1 nanomolar in peripheral circulation1. This substantial concentration gradient (several hundred-fold) explains why systemic administration of exogenous testosterone is ineffective in significantly elevating intra-follicular androgen levels. The key to effective androgen action in the follicle lies in its local production.
Furthermore, as follicles mature and approach ovulation, there is a marked increase in aromatase expression. This enzyme efficiently converts the high intra-follicular androgen concentrations into oestrogens,maintaining a delicate balance essential for successful follicular maturation and ovulation.
4. Inhibin B and Thecal Androgen Synthesis: A Synergistic Mechanism
Expanding on the role of inhibin B, Professor Andersen presented data demonstrating that inhibin B synergises with Luteinizing Hormone (LH) to drive thecal androgen synthesis. Intra-follicular inhibin B levels exhibit a characteristic peak around cycle days 7-9, a period critical for dominant follicle selection. This temporal correlation strongly suggests that inhibin B plays a crucial role in orchestrating the local hormonal necessary for optimal dominant follicle development1.
5. Quantitative Relationship Between Inhibin B and Follicular Parameters
Analysis of inhibin B concentrations in fluid aspirated from small antral follicles during natural menstrual cycles revealed robust associations with androgen levels and gene expression profiles in corresponding granulosa cells. The following table summarises these quantitative relationships:
| Quartile of Inhibin-B Concentration | Androstenedione (nmol/L) | Testosterone (nmol/L) | FSHR (x1000) | LHR (x1000) | CYP19A1 (x1000) | AR (x1000) |
|---|---|---|---|---|---|---|
| 0-25% | 2114±175 | 155±14 | 124±21 | 2.0±0.8 | 19±3 | 84±17 |
| 25-50% | 1930±150 | 194±18 | 242±58 | 2.5±0.7 | 21±7 | 123±34 |
| 50-75% | 2687±169 | 290±25 | 256±39 | 3.6±1.3 | 39±12 | 81±17 |
| 75-100% | 2991±190 | 254±17 | 275±114 | 9.1±2.7 | 188±43 | 66±14 |
Statistical analysis (Spearman correlation) demonstrated highly significant positive correlations between inhibin B concentrations and Androstenedione (P<5x10-6), Testosterone (P<4x10-9, FSHR (P<0.001), LHR (P<3x10-5), and CYP19A1 (P<2x10-6). Notably, Androgen Receptor (AR) expression did not show a significant correlation (P>0.10)2.
This data illustrates that elevated inhibin B concentrations are associated with increased intra-follicular levels of androstenedione and testosterone, alongside enhanced expression of FSHR and LHR receptors, and the aromatase enzyme (CYP19A1) in granulosa cells. This evidence strongly supports the concept that inhibin B is a critical regulator in establishing an androgen-rich microenvironment within the follicle, which is indispensable for its progressive development and steroidogenic capacity.
6. Impact of FSH Isoforms on Follicular Development: Tailoring Stimulation Protocols
Professor Andersen presented evidence demonstrating the differential effects of acidic versus less acidic FSH isoforms on ovarian follicular development within a clinical context. Studies have consistently shown that the daily subcutaneous administration of more acidic FSH isoforms results in a greater number of developing follicles and higher serum inhibin B concentrations when compared to the administration of more basic FSH isoforms3.
Specifically, clinical data indicated a statistically significant increase in the number of 11-15 mm follicles observed on Day 10 in volunteers who received more acidic FSH isoforms (14 follicles vs. 8 follicles, with a p-value of 0.01)[3]. Furthermore, the total follicular volume exhibited a more pronounced increase from Day 8 to Day 10 in the group treated with more acidic FSH, despite comparable serum oestradiol (E2) concentrations between the treatment groups3.
7. Inhibin B Concentrations and FSH Isoform Acidity
Analysis of serum inhibin B concentrations revealed significantly higher levels in the group receiving more acidic FSH isoforms. This difference was statistically significant for both the maximum concentration (p=0.008) and the area under the curve (AUC) (p=0.036)[3]. These findings provide direct support for the hypothesis that acidic FSH isoforms actively stimulate a greater output of inhibin B, which subsequently promotes intra-follicular androgen production and enhances the sensitivity of follicles to FSH. This mechanism is crucial for optimising follicular recruitment and growth.
These observations underscore that the specific type of FSH isoform administered can profoundly influence the trajectory of follicle development. The advent of advanced chromatographic separation coupled with recombinant technology may offer the capability to precisely control the FSH isoform profile, thereby enabling the potential to mimic the nuanced physiological changes observed during a natural menstrual cycle3.
8. Outlook for Ovarian Stimulation Mimicking the Natural Cycle: A Physiologically Guided Approach
Based on the insights presented, Professor Andersen proposed a compelling rationale for adopting a sequential protocol for ovarian stimulation. This approach aims to mimic the dynamic hormonal shifts observed during a natural menstrual cycle, thereby potentially optimising treatment outcomes. The proposed protocol would involve a two-phase administration:
- Initiation with Acidic FSH Isoforms:
Administering acidic FSH isoforms during the first half of the follicular phase. This strategy is supported by evidence demonstrating that these isoforms lead to enhanced follicular recruitment in a clinical setting and stimulate a higher output of inhibin B. This, in turn, promotes increased intra-follicular androgen levels and FSH sensitivity, creating an optimal environment for early follicular development. - Transition to Less Acidic FSH Isoforms:
A subsequent shift to less acidic FSH isoforms in the second half of the follicular phase, with the timing of this transition being guided by circulating oestradiol (E2) levels.
Professor Andersen noted that, to his knowledge, a direct clinical study testing such a sequential, physiologically guided approach has yet to be conducted. Current clinical trial designs often focus on comparative analyses of different recombinant FSH preparations rather than exploring protocols that precisely emulate the natural, dynamic changes in FSH isoform profiles throughout the menstrual cycle4. This represents a significant area for future research and clinical innovation.
Conclusion
Professor Andersen’s presentation provided an exploration of the critical roles of androgens and FSH isoforms in ovarian follicular development. The interplay between inhibin B, local androgen synthesis, and the modulation of FSH receptor expression offers a more nuanced understanding of follicular dynamics. The insights presented advocate for a shift towards a more physiologically guided approach to ovarian stimulation.
Specifically, the adoption of sequential FSH isoform administration holds significant promise for optimising fertility treatment outcomes by more closely replicating the natural biological processes of the menstrual cycle.
